EXS13590_1022_EN_UK ASCO Flashcard

ASCO® 2022 Clinical Practice Guidelines1

For patients with ER+, HER2-, early-stage, invasive breast cancer Oncotype DX® test

Postmenopausal or age >50 years

Premenopausal or age ≤50 years

N0



N1



N0



N1

Qualifying statement: The Oncotype DX® test is prognostic and may be used for shared patient-physician treatment decision making

Evidence High Recommendation Strong*

MammaPrint®

EndoPredict®

Prosigna®

Evidence Intermediate Recommendation Moderate

Evidence Intermediate Recommendation Moderate

High clinical risk only

High clinical risk only

Evidence Intermediate Recommendation Strong

1. Andre et al. J Clin Oncol. 2022. * for N0 and postmenopausal N1 patients ASCO is a trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy.

Other trademarks are the property of their respective owners.

ASCO® 2022 Clinical Practice Guidelines ASCO® Guidelines 2022 strongly recommend the Oncotype DX® test based on TAILORx and RxPONDER study results1

• The Oncotype DX test is strongly recommended for all N0 and postmenopausal N1 patients • For premenopausal N0 patients the Oncotype DX test is the only recommended assay • Recommendation is broad and independent of any clinical risk classification • Recommendation level is strong and with high evidence quality based on ®

®

ASCO® recommendation framework

1. Andre et al. J Clin Oncol. 2022.

Customer Support: 020 3031 8087 europeansupport@exactsciences.com www.exactsciences.com/uk www.oncotypeiq.com/en-GB/

Exact Sciences UK, Ltd. Scott House The Concourse Waterloo Station London SE1 7LY

ASCO is a trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy.

Oncotype DX Breast Recurrence Score and Oncotype DX are registered trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved. EXS13590_1022_EN_UK